{"id":145997,"date":"2025-03-10T15:44:53","date_gmt":"2025-03-10T10:14:53","guid":{"rendered":"https:\/\/tradebrains.in\/features\/?p=145997"},"modified":"2025-03-18T17:03:34","modified_gmt":"2025-03-18T11:33:34","slug":"pharma-stocks-to-benefit-as-diabetes-drug-price-is-se-to-drop-by-90-from-90-to-9","status":"publish","type":"post","link":"https:\/\/tradebrains.in\/features\/pharma-stocks-to-benefit-as-diabetes-drug-price-is-se-to-drop-by-90-from-90-to-9\/","title":{"rendered":"Pharma stocks to benefit after Diabetes drug prices expected to drop by 90%"},"content":{"rendered":"<div class=\"trade-content_2\" style=\"margin-left: auto;margin-right: auto;text-align: center;\" id=\"trade-3742216339\"><p><a href=\"https:\/\/tradebrains.in\/get\/telegram\/\"><img decoding=\"async\" class=\"alignnone wp-image-101992\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/01\/telegram-channel-300x119.png\" alt=\"\" width=\"148\" height=\"59\" \/><\/a> <a href=\"https:\/\/news.google.com\/publications\/CAAqBwgKMN3Epgswxc--Aw?hl=en-IN&amp;gl=IN&amp;ceid=IN%3Aen\"><img decoding=\"async\" class=\"alignnone wp-image-123430\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-300x82.png\" alt=\"follow-on-google-news\" width=\"222\" height=\"61\" srcset=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-300x82.png 300w, https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-150x41.png 150w, https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news.png 468w\" sizes=\"(max-width: 222px) 100vw, 222px\" \/><\/a><\/p>\n<\/div><p>German pharma giant Boehringer Ingelheim\u2019s diabetes drug Empagliflozin (type 2 diabetes) which is sold under the brand name Jardiance, its patent expiring on March 11, can allow Indian Pharma companies to launch affordable generics as per Times of India. Empagliflozin works in the Kidneys to prevent absorption of glucose or blood sugar, and this helps to lower blood sugar levels.<\/p><div class=\"trade-content_7\" style=\"margin-left: auto;margin-right: auto;text-align: center;\" id=\"trade-1273934456\"><!-- Composite Start --> \r\n <div id=\"M923760ScriptRootC1549812\"> \r\n <\/div> \r\n <script src=\"https:\/\/jsc.mgid.com\/t\/r\/tradebrains.in.1549812.js\" async> \r\n <\/script> \r\n <!-- Composite End --><\/div><p>With over 10.1 crore Indians living with diabetes as per ICMR study, this shift can ease financial burdens and improve treatment access. Generic versions will cost Rs. 9 to 14 per tablet, which can significantly reduce prices by up to 90 percent from around Rs. 60 per tablet as per sources. This price reduction follows a similar trend seen with newer treatments like <a href=\"https:\/\/henrymeds.com\/sublingual-semaglutide-drops\/\" target=\"_blank\" rel=\"noreferrer noopener\">sublingual semaglutide<\/a>, which offers an alternative delivery method for patients who struggle with traditional medications.<\/p><p>India&#8217;s diabetes drug market, which is valued at Rs. 20,000 crore, has grown by 43 percent since 2021. Cheaper alternatives will aid heart and kidney health while reducing hospitalization costs.&nbsp;<\/p><p>Companies that leverage bulk active pharmaceutical ingredients can lower production costs and expand their distribution. The move can benefit both businesses and millions of diabetic patients who can afford treatment. Indian Pharma companies can benefit from this development.&nbsp;<\/p><div class=\"trade-content_5\" id=\"trade-2814393174\"><script async src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-4023722985638610\"\r\n     crossorigin=\"anonymous\"><\/script>\r\n<!-- in_content_2_news -->\r\n<ins class=\"adsbygoogle\"\r\n     style=\"display:block\"\r\n     data-ad-client=\"ca-pub-4023722985638610\"\r\n     data-ad-slot=\"7925020301\"\r\n     data-ad-format=\"auto\"\r\n     data-full-width-responsive=\"true\"><\/ins>\r\n<script>\r\n     (adsbygoogle = window.adsbygoogle || []).push({});\r\n<\/script><\/div><p><strong>Stocks that might benefit from the lower diabetic drug costs from the off-patent of Jardiance are as follows<\/strong><\/p><h2 class=\"wp-block-heading has-medium-font-size\"><strong><a href=\"https:\/\/portal.tradebrains.in\/stocks\/MANKIND\" target=\"_blank\" rel=\"noreferrer noopener\">Mankind Pharma&nbsp;<\/a><\/strong><\/h2><p>The company was founded in 1991 and is one of the leading Indian pharmaceutical company known for affordable and quality healthcare products. It operates in 34 countries, offering a wide range of pharmaceutical and consumer healthcare solutions.<\/p><p>With a market capitalization of Rs. 93,253.06 Crores, the shares of Mankind Pharma Limited were trading at Rs. 2,260.25 per equity share, down 2.38 percent from its previous day\u2019s close price of Rs. 2,315.45.<\/p><h2 class=\"wp-block-heading has-medium-font-size\"><strong><a href=\"https:\/\/portal.tradebrains.in\/stocks\/TORNTPHARM\" target=\"_blank\" rel=\"noreferrer noopener\">Torrent Pharmaceuticals<\/a><\/strong><\/h2><p>This Torrent Group company, which is one of the leading Indian pharma company that specializes in cardiovascular, CNS, GI, and women&#8217;s healthcare. It operates in over 50 countries with a strong presence in Brazil and Germany, offering branded generics and generic products.<\/p><p>With a market capitalization of Rs. 1,04,485.26 Crores, the shares of Torrent Pharmaceuticals Limited were trading at Rs. 3,087.35 per equity share, up 0.50 percent from its previous day\u2019s close price of Rs. 3,072.10.<\/p><h2 class=\"wp-block-heading has-medium-font-size\"><strong><a href=\"https:\/\/portal.tradebrains.in\/stocks\/ALKEM\" target=\"_blank\" rel=\"noreferrer noopener\">Alkem Laboratories<\/a><\/strong><\/h2><p>This company is into manufacturing and marketing generic and specialty products across multiple therapeutic areas. It operates in over 40 countries, with a strong presence in the US and a portfolio of over 800 brands in India.<\/p><div class=\"trade-content-10\" id=\"trade-394370894\"><script async src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-4023722985638610\"\r\n     crossorigin=\"anonymous\"><\/script>\r\n<!-- in_content_3_news -->\r\n<ins class=\"adsbygoogle\"\r\n     style=\"display:block\"\r\n     data-ad-client=\"ca-pub-4023722985638610\"\r\n     data-ad-slot=\"2969612066\"\r\n     data-ad-format=\"auto\"\r\n     data-full-width-responsive=\"true\"><\/ins>\r\n<script>\r\n     (adsbygoogle = window.adsbygoogle || []).push({});\r\n<\/script><\/div><p>With a market capitalization of Rs. 55,402.24 Crores, the shares of Alkem Laboratories Limited were trading at Rs. 4,633.65 per equity share, down 1.91 percent from its previous day\u2019s close price of Rs. 4,723.95.<\/p><h2 class=\"wp-block-heading has-medium-font-size\"><strong><a href=\"https:\/\/portal.tradebrains.in\/stocks\/DRREDDY\">Dr Reddy\u2019s Laboratories<\/a><\/strong><\/h2><p>This is a global pharmaceutical company based in Hyderabad, India. It manufactures and markets a wide range of pharmaceuticals, including generics, biosimilars, and APIs, serving customers worldwide with affordable and innovative medicines.<\/p><p>With a market capitalization of Rs. 93,436.68 Crores, the shares of Dr Reddy\u2019s Laboratories Limited were trading at Rs. 1,119.80 per equity share, down 1.15 percent from its previous day\u2019s close price of Rs. 1,132.80.<\/p><h2 class=\"wp-block-heading has-medium-font-size\"><a href=\"https:\/\/portal.tradebrains.in\/stocks\/LUPIN\"><strong>Lupin<\/strong>&nbsp;<\/a><\/h2><p>Lupin specializes in generics, branded generics, APIs, biosimilars, and specialty medicines, serving over 100 markets with a diverse portfolio of over 1,200 products.<\/p><p>With a market capitalization of Rs. 91,929.08 Crores, the shares of Lupin Limited were trading at Rs. 2,013.60 per equity share, down 0.75 percent from its previous day\u2019s close price of Rs. 2,028.90.<\/p><blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\"><p><strong>Written by Santhosh<\/strong><\/p><\/blockquote><p class=\"has-medium-font-size\"><strong>Disclaimer<\/strong><\/p><div class=\"wp-block-image\"><figure class=\"aligncenter size-medium\"><img decoding=\"async\" width=\"300\" height=\"300\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/02\/warning-disclaimer-300x300.png\" alt=\"\" class=\"wp-image-26306\"\/><\/figure><\/div><p><strong>The views and investment tips expressed by investment experts\/broking houses\/rating agencies on <a href=\"http:\/\/tradebrains.in\/\">tradebrains.in<\/a> are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing<\/strong>.<\/p><div class=\"trade-after-content\" id=\"trade-118700918\"><div id=\"taboola-below-article-thumbnails\"><\/div>\r\n<script type=\"text\/javascript\">\r\n  window._taboola = window._taboola || [];\r\n  _taboola.push({\r\n    mode: 'alternating-thumbnails-a',\r\n    container: 'taboola-below-article-thumbnails',\r\n    placement: 'Below Article Thumbnails',\r\n    target_type: 'mix'\r\n  });\r\n<\/script>\r\n<script type=\"text\/javascript\">\r\n  window._taboola = window._taboola || [];\r\n  _taboola.push({flush: true});\r\n<\/script><\/div>","protected":false},"excerpt":{"rendered":"<p>German pharma giant Boehringer Ingelheim\u2019s diabetes drug Empagliflozin (type 2 diabetes) which is sold under the brand name Jardiance, its patent expiring on March 11, can allow Indian Pharma companies to launch affordable generics as per Times of India. Empagliflozin works in the Kidneys to prevent absorption of glucose or blood sugar, and this helps [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":49884,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[31,1789],"tags":[19947,24174,2383,19821,948,936,3157,27431],"class_list":["post-145997","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-trending-news","tag-alkem-laboratories","tag-dr-reddys-laboratories-3","tag-lupin","tag-mankind-pharma","tag-stock-market","tag-stock-market-news","tag-stock-to-watch","tag-torrent-pharmaceuticals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v20.5 (Yoast SEO v25.0) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma stocks to benefit after Diabetes drug prices expected to drop by 90% - Trade Brains Features<\/title>\n<meta name=\"description\" content=\"German pharma giant Boehringer Ingelheim\u2019s diabetes drug Empagliflozin (type 2 diabetes) which is sold under the brand name Jardiance, its patent expiring on March 11, can allow Indian Pharma companies to launch affordable generics as per Times of India.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/tradebrains.in\/features\/pharma-stocks-to-benefit-as-diabetes-drug-price-is-se-to-drop-by-90-from-90-to-9\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma stocks to benefit after Diabetes drug prices expected to drop by 90%\" \/>\n<meta property=\"og:description\" content=\"German pharma giant Boehringer Ingelheim\u2019s diabetes drug Empagliflozin (type 2 diabetes) which is sold under the brand name Jardiance, its patent expiring on March 11, can allow Indian Pharma companies to launch affordable generics as per Times of India.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/tradebrains.in\/features\/pharma-stocks-to-benefit-as-diabetes-drug-price-is-se-to-drop-by-90-from-90-to-9\/\" \/>\n<meta property=\"og:site_name\" content=\"Trade Brains Features\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/TradeBrainsOfficial\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-10T10:14:53+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-18T11:33:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/06\/Pharma-1-Cover-Image.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"854\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Trade Brains\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@TradeBrainsGrp\" \/>\n<meta name=\"twitter:site\" content=\"@TradeBrainsGrp\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Trade Brains\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stocks-to-benefit-as-diabetes-drug-price-is-se-to-drop-by-90-from-90-to-9\/\",\"url\":\"https:\/\/tradebrains.in\/features\/pharma-stocks-to-benefit-as-diabetes-drug-price-is-se-to-drop-by-90-from-90-to-9\/\",\"name\":\"Pharma stocks to benefit after Diabetes drug prices expected to drop by 90% - Trade Brains Features\",\"isPartOf\":{\"@id\":\"https:\/\/tradebrains.in\/features\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stocks-to-benefit-as-diabetes-drug-price-is-se-to-drop-by-90-from-90-to-9\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stocks-to-benefit-as-diabetes-drug-price-is-se-to-drop-by-90-from-90-to-9\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/06\/Pharma-1-Cover-Image.jpg\",\"datePublished\":\"2025-03-10T10:14:53+00:00\",\"dateModified\":\"2025-03-18T11:33:34+00:00\",\"author\":{\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666\"},\"description\":\"German pharma giant Boehringer Ingelheim\u2019s diabetes drug Empagliflozin (type 2 diabetes) which is sold under the brand name Jardiance, its patent expiring on March 11, can allow Indian Pharma companies to launch affordable generics as per Times of India.\",\"breadcrumb\":{\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stocks-to-benefit-as-diabetes-drug-price-is-se-to-drop-by-90-from-90-to-9\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/tradebrains.in\/features\/pharma-stocks-to-benefit-as-diabetes-drug-price-is-se-to-drop-by-90-from-90-to-9\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stocks-to-benefit-as-diabetes-drug-price-is-se-to-drop-by-90-from-90-to-9\/#primaryimage\",\"url\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/06\/Pharma-1-Cover-Image.jpg\",\"contentUrl\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/06\/Pharma-1-Cover-Image.jpg\",\"width\":1280,\"height\":854},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stocks-to-benefit-as-diabetes-drug-price-is-se-to-drop-by-90-from-90-to-9\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/tradebrains.in\/features\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pharma stocks to benefit after Diabetes drug prices expected to drop by 90%\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/tradebrains.in\/features\/#website\",\"url\":\"https:\/\/tradebrains.in\/features\/\",\"name\":\"Trade Brains\",\"description\":\"Stock Market NSE\/BSE Latest News\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/tradebrains.in\/features\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666\",\"name\":\"Trade Brains\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g\",\"caption\":\"Trade Brains\"},\"sameAs\":[\"http:\/\/tradebrains.in\/\"],\"url\":\"https:\/\/tradebrains.in\/features\/author\/trade-brains\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma stocks to benefit after Diabetes drug prices expected to drop by 90% - Trade Brains Features","description":"German pharma giant Boehringer Ingelheim\u2019s diabetes drug Empagliflozin (type 2 diabetes) which is sold under the brand name Jardiance, its patent expiring on March 11, can allow Indian Pharma companies to launch affordable generics as per Times of India.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/tradebrains.in\/features\/pharma-stocks-to-benefit-as-diabetes-drug-price-is-se-to-drop-by-90-from-90-to-9\/","og_locale":"en_US","og_type":"article","og_title":"Pharma stocks to benefit after Diabetes drug prices expected to drop by 90%","og_description":"German pharma giant Boehringer Ingelheim\u2019s diabetes drug Empagliflozin (type 2 diabetes) which is sold under the brand name Jardiance, its patent expiring on March 11, can allow Indian Pharma companies to launch affordable generics as per Times of India.","og_url":"https:\/\/tradebrains.in\/features\/pharma-stocks-to-benefit-as-diabetes-drug-price-is-se-to-drop-by-90-from-90-to-9\/","og_site_name":"Trade Brains Features","article_publisher":"https:\/\/www.facebook.com\/TradeBrainsOfficial\/","article_published_time":"2025-03-10T10:14:53+00:00","article_modified_time":"2025-03-18T11:33:34+00:00","og_image":[{"width":1280,"height":854,"url":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/06\/Pharma-1-Cover-Image.jpg","type":"image\/jpeg"}],"author":"Trade Brains","twitter_card":"summary_large_image","twitter_creator":"@TradeBrainsGrp","twitter_site":"@TradeBrainsGrp","twitter_misc":{"Written by":"Trade Brains","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/tradebrains.in\/features\/pharma-stocks-to-benefit-as-diabetes-drug-price-is-se-to-drop-by-90-from-90-to-9\/","url":"https:\/\/tradebrains.in\/features\/pharma-stocks-to-benefit-as-diabetes-drug-price-is-se-to-drop-by-90-from-90-to-9\/","name":"Pharma stocks to benefit after Diabetes drug prices expected to drop by 90% - Trade Brains Features","isPartOf":{"@id":"https:\/\/tradebrains.in\/features\/#website"},"primaryImageOfPage":{"@id":"https:\/\/tradebrains.in\/features\/pharma-stocks-to-benefit-as-diabetes-drug-price-is-se-to-drop-by-90-from-90-to-9\/#primaryimage"},"image":{"@id":"https:\/\/tradebrains.in\/features\/pharma-stocks-to-benefit-as-diabetes-drug-price-is-se-to-drop-by-90-from-90-to-9\/#primaryimage"},"thumbnailUrl":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/06\/Pharma-1-Cover-Image.jpg","datePublished":"2025-03-10T10:14:53+00:00","dateModified":"2025-03-18T11:33:34+00:00","author":{"@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666"},"description":"German pharma giant Boehringer Ingelheim\u2019s diabetes drug Empagliflozin (type 2 diabetes) which is sold under the brand name Jardiance, its patent expiring on March 11, can allow Indian Pharma companies to launch affordable generics as per Times of India.","breadcrumb":{"@id":"https:\/\/tradebrains.in\/features\/pharma-stocks-to-benefit-as-diabetes-drug-price-is-se-to-drop-by-90-from-90-to-9\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/tradebrains.in\/features\/pharma-stocks-to-benefit-as-diabetes-drug-price-is-se-to-drop-by-90-from-90-to-9\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tradebrains.in\/features\/pharma-stocks-to-benefit-as-diabetes-drug-price-is-se-to-drop-by-90-from-90-to-9\/#primaryimage","url":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/06\/Pharma-1-Cover-Image.jpg","contentUrl":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/06\/Pharma-1-Cover-Image.jpg","width":1280,"height":854},{"@type":"BreadcrumbList","@id":"https:\/\/tradebrains.in\/features\/pharma-stocks-to-benefit-as-diabetes-drug-price-is-se-to-drop-by-90-from-90-to-9\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/tradebrains.in\/features\/"},{"@type":"ListItem","position":2,"name":"Pharma stocks to benefit after Diabetes drug prices expected to drop by 90%"}]},{"@type":"WebSite","@id":"https:\/\/tradebrains.in\/features\/#website","url":"https:\/\/tradebrains.in\/features\/","name":"Trade Brains","description":"Stock Market NSE\/BSE Latest News","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/tradebrains.in\/features\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666","name":"Trade Brains","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g","caption":"Trade Brains"},"sameAs":["http:\/\/tradebrains.in\/"],"url":"https:\/\/tradebrains.in\/features\/author\/trade-brains\/"}]}},"_links":{"self":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/145997","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/comments?post=145997"}],"version-history":[{"count":3,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/145997\/revisions"}],"predecessor-version":[{"id":146339,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/145997\/revisions\/146339"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/media\/49884"}],"wp:attachment":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/media?parent=145997"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/categories?post=145997"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/tags?post=145997"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}